2025 Europe Antibodies In Oncology Market Revenue Opportunities Report
Description
The 2025 Europe Antibodies In Oncology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in Europe include argenx, Genmab, Roche, and AstraZeneca. Argenx, headquartered in Belgium, is Europe's most valuable biotech company focused on antibody-based therapies targeting complex diseases including cancer, with an emphasis on antibody engineering techniques like efgartigimod and bispecific antibodies. Genmab, based in Denmark, excels in antibody therapies and has developed Darzalex, a leading antibody drug for multiple myeloma, while pioneering innovative bispecific antibody technologies such as DuoBody, collaborating with Janssen and AbbVie.
Roche, a Swiss multinational, is a pioneer in oncology and bispecific antibodies, offering blockbuster drugs like Tecentriq for various cancers and investing heavily in immuno-oncology advancements and diagnostics across Europe. AstraZeneca, headquartered in the UK/Sweden, focuses on bispecific antibody development through divisions Alexion and MedImmune, aiming to target dual disease pathways in cancer and autoimmune disorders with an expanding pipeline reflecting strong commitment to this field. These companies lead Europe’s antibody-based immuno-oncology innovation through cutting-edge research, strategic partnerships, and robust clinical pipelines.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in Europe include argenx, Genmab, Roche, and AstraZeneca. Argenx, headquartered in Belgium, is Europe's most valuable biotech company focused on antibody-based therapies targeting complex diseases including cancer, with an emphasis on antibody engineering techniques like efgartigimod and bispecific antibodies. Genmab, based in Denmark, excels in antibody therapies and has developed Darzalex, a leading antibody drug for multiple myeloma, while pioneering innovative bispecific antibody technologies such as DuoBody, collaborating with Janssen and AbbVie.
Roche, a Swiss multinational, is a pioneer in oncology and bispecific antibodies, offering blockbuster drugs like Tecentriq for various cancers and investing heavily in immuno-oncology advancements and diagnostics across Europe. AstraZeneca, headquartered in the UK/Sweden, focuses on bispecific antibody development through divisions Alexion and MedImmune, aiming to target dual disease pathways in cancer and autoimmune disorders with an expanding pipeline reflecting strong commitment to this field. These companies lead Europe’s antibody-based immuno-oncology innovation through cutting-edge research, strategic partnerships, and robust clinical pipelines.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
